Posted by Michael Wonder on 26 Dec 2021
Eagle Pharmaceuticals receives FDA approval for vasopressin
15 December 2021 - Company is first to file an ANDA referencing Vasostrict, which had total U.S. sales of $786 million in 2020.
Eagle Pharmaceuticals today announced that the U.S. FDA has approved the Company’s abbreviated new drug application for vasopressin.
This approval follows the recent U.S. District Court for the District of Delaware decision holding that Eagle’s proposed vasopressin product does not infringe any of the patents Par Pharmaceutical, Inc. et al. asserted against the Company.
